In the therapy group, a significant decrease of tumour perfusion (WiAUC) was observed following the one-week treatment course with combined anti-PD-L1/anti-CTLA-4 immunotherapy (23767 ± 16937 a.u. at baseline to 8054 ± 10083 a.u. at follow-up; p = 0.008). This evidence concerns the gene CTLA4 and neoplasm.